Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical

Drug Profile

Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical

Alternative Names: COL-003; Oxycodone abuse resistant - Collegium Pharmaceutical; Oxycodone DETERx®; Oxycodone DETERx®ER; Oxycodone DETERx®extended-release; Oxycodone extended release - Collegium pharmaceutical; XTAMPZA ER

Latest Information Update: 23 Apr 2017

Price : $50

At a glance

  • Originator Collegium Pharmaceutical
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 16 Mar 2017 Adverse events data from a phase III trial in Pain released by Collegium Pharmaceutical
  • 01 Feb 2017 Pharmacodynamics data from an oral human abuse potential clinical trial released by Collegium Pharmaceutical
  • 05 Oct 2016 Collegium Pharmaceutical files sNDA to enhance the label for oxycodone extended-release treatment of patients with Pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top